Duopharma Biotech Berhad Statistics
Total Valuation
KLSE:DPHARMA has a market cap or net worth of MYR 1.14 billion. The enterprise value is 1.39 billion.
Market Cap | 1.14B |
Enterprise Value | 1.39B |
Important Dates
The next estimated earnings date is Friday, May 16, 2025.
Earnings Date | May 16, 2025 |
Ex-Dividend Date | Mar 5, 2025 |
Share Statistics
KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has increased by 0.36% in one year.
Current Share Class | n/a |
Shares Outstanding | 961.94M |
Shares Change (YoY) | +0.36% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.30% |
Owned by Institutions (%) | 71.16% |
Float | 450.08M |
Valuation Ratios
The trailing PE ratio is 18.12 and the forward PE ratio is 13.14. KLSE:DPHARMA's PEG ratio is 0.68.
PE Ratio | 18.12 |
Forward PE | 13.14 |
PS Ratio | 1.39 |
PB Ratio | 1.60 |
P/TBV Ratio | 1.62 |
P/FCF Ratio | 18.99 |
P/OCF Ratio | 13.62 |
PEG Ratio | 0.68 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.84, with an EV/FCF ratio of 23.20.
EV / Earnings | 22.13 |
EV / Sales | 1.70 |
EV / EBITDA | 9.84 |
EV / EBIT | 13.83 |
EV / FCF | 23.20 |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.73.
Current Ratio | 4.08 |
Quick Ratio | 2.65 |
Debt / Equity | 0.73 |
Debt / EBITDA | 3.66 |
Debt / FCF | 8.63 |
Interest Coverage | 3.89 |
Financial Efficiency
Return on equity (ROE) is 8.97% and return on invested capital (ROIC) is 5.09%.
Return on Equity (ROE) | 8.97% |
Return on Assets (ROA) | 4.60% |
Return on Invested Capital (ROIC) | 5.09% |
Return on Capital Employed (ROCE) | 8.36% |
Revenue Per Employee | 415,787 |
Profits Per Employee | 32,011 |
Employee Count | 1,957 |
Asset Turnover | 0.60 |
Inventory Turnover | 2.08 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.84% in the last 52 weeks. The beta is 0.77, so KLSE:DPHARMA's price volatility has been lower than the market average.
Beta (5Y) | 0.77 |
52-Week Price Change | -0.84% |
50-Day Moving Average | 1.20 |
200-Day Moving Average | 1.24 |
Relative Strength Index (RSI) | 48.62 |
Average Volume (20 Days) | 189,160 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:DPHARMA had revenue of MYR 813.70 million and earned 62.65 million in profits. Earnings per share was 0.07.
Revenue | 813.70M |
Gross Profit | 301.54M |
Operating Income | 100.26M |
Pretax Income | 80.02M |
Net Income | 62.65M |
EBITDA | 137.34M |
EBIT | 100.26M |
Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 264.55 million in cash and 515.82 million in debt, giving a net cash position of -251.28 million or -0.26 per share.
Cash & Cash Equivalents | 264.55M |
Total Debt | 515.82M |
Net Cash | -251.28M |
Net Cash Per Share | -0.26 |
Equity (Book Value) | 709.15M |
Book Value Per Share | 0.74 |
Working Capital | 548.42M |
Cash Flow
In the last 12 months, operating cash flow was 83.34 million and capital expenditures -23.57 million, giving a free cash flow of 59.77 million.
Operating Cash Flow | 83.34M |
Capital Expenditures | -23.57M |
Free Cash Flow | 59.77M |
FCF Per Share | 0.06 |
Margins
Gross margin is 37.06%, with operating and profit margins of 12.32% and 7.70%.
Gross Margin | 37.06% |
Operating Margin | 12.32% |
Pretax Margin | 9.83% |
Profit Margin | 7.70% |
EBITDA Margin | 16.88% |
EBIT Margin | 12.32% |
FCF Margin | 7.35% |
Dividends & Yields
This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.54%.
Dividend Per Share | 0.03 |
Dividend Yield | 2.54% |
Dividend Growth (YoY) | 30.43% |
Years of Dividend Growth | 1 |
Payout Ratio | 42.99% |
Buyback Yield | -0.36% |
Shareholder Yield | 2.18% |
Earnings Yield | 5.52% |
FCF Yield | 5.27% |
Stock Splits
The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.
Last Split Date | Sep 6, 2021 |
Split Type | Forward |
Split Ratio | 1.3333333333 |
Scores
KLSE:DPHARMA has an Altman Z-Score of 2.74. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.74 |
Piotroski F-Score | n/a |